Why the study?
As a rare disorder, large scale clinical trial data to guide the management of myotonic dystrophy are largely lacking, prompting the need for clinical care recommendations.
Provides expert consensus recommendations for the cardiac surveillance and management of adults with myotonic dystrophy.
May support arrhythmia and LV dysfunction surveillance in myotonic dystrophy; leaves open optimal intervals and type-specific risks.
Myotonic dystrophy is an inherited systemic disorder affecting skeletal muscle and the heart. Genetic testing for myotonic dystrophy is diagnostic and identifies those at risk for cardiac complications. The 2 major genetic forms of myotonic dystrophy, type 1 and type 2, differ in genetic etiology yet share clinical features. The cardiac management of myotonic dystrophy should include surveillance for arrhythmias and left ventricular dysfunction, both of which occur in progressive manner and contribute to morbidity and mortality. To promote the development of care guidelines for myotonic dystrophy, the Myotonic Foundation solicited the input of care experts and organized the drafting of these recommendations. As a rare disorder, large scale clinical trial data to guide the management of myotonic dystrophy are largely lacking. The following recommendations represent expert consensus opinion from those with experience in the management of myotonic dystrophy, in part supported by literature-based evidence where available.
No takes yet. Share an insight, caveat, or question.
McNally et al. (2020) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: